行情

CELG-RT

CELG-RT

Celgene
NYSE

实时行情|Nasdaq Last Sale

0.2700
-0.0700
-20.59%
已收盘, 16:17 03/04 EST
开盘
0.3000
昨收
0.3400
最高
0.3000
最低
0.2500
成交量
10.44万
成交额
--
52周最高
0.6100
52周最低
0.2500
市值
1.92亿
市盈率(TTM)
0.0337
分时
5日
1月
3月
1年
5年
港报财经评论：内地基金损手，慎防北水回朝--信报3月5日
reuters.com · 13小时前
Stocks making the biggest moves after hours: Tiffany & Co., L Brands, Uber and more
See which stocks are posting big moves after the bell on Wednesday.
CNBC.com · 2019/11/20 23:05
Stocks making the biggest moves after hours: ServiceNow, Alliance Data, AMC Entertainment and more
See which stocks are posting big moves after the bell on Monday.
CNBC.com · 2019/11/18 23:13
Biotech sector looks to build on strong October
Michael Yee, Jefferies biotech analyst, discusses the IBB's really good October and whether the sector can continue to build on its big run.
CNBC.com · 2019/11/04 18:58
Biotech stocks win October, rallying 8%
The biotechnology sector is up over 8% in October, lead by large-cap companies Biogen, Amgen and Celgene.
CNBC.com · 2019/10/31 15:18
What to watch today: A third rate cut in place, China doubts the deal, and Peugeot, Fiat make it official
U.S. stock futures are falling before the final session of October, following a Bloomberg report that Chinese officials were unsure they could reach a long-term trade deal with the U.S.
CNBC.com · 2019/10/31 10:35
Biotech stocks soar following shock Biogen drug announcement
Biotech stocks traded higher on Tuesday after Biogen said it would seek approval for its Alzheimer's drug.
CNBC.com · 2019/10/22 15:45
Everything Jim Cramer said about the stock market on 'Mad Money,' including the week ahead, iPhone sales, AbbVie vs. Bristol-Myers and Zscaler CEO
Jim Cramer previews the week ahead of earnings and stock market news, projects iPhone sales in China, breaks down AbbVie and Bristol-Myers' latest deals and interviews Zscaler CEO Jay Chaudhry.
CNBC.com · 2019/09/21 00:18
更多
财务预测
暂无数据
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解CELG-RT最新的财务预测，通过CELG-RT每股收益，每股净资产，每股现金流等数据分析Celgene近期的经营情况，然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-1.53%
制药与医学研究
-2.13%
高管信息
Chairman/Chief Executive Officer/Director
Mark Alles
Executive Vice President
Peter Kellogg
Corporate Executive
Terrie Curran
Corporate Executive
Rupert Vessey
Corporate Executive
Michael Pehl
Executive Vice President/General Counsel
Jonathan Biller
Executive Vice President/General Counsel/Secretary
Gerald Masoudi
Chief Financial Officer/Executive Vice President
David Elkins
Lead Director
Michael Casey
Director
Hans Bishop
Director
Julia Haller
Independent Director
Richard Barker
Director
Patricia Hall
Independent Director
Michael Bonney
公告日期
每股分红
除权日期
--
每股分红:USD 6.932592
2013/10/08
  • 全部
  • 财务报告
  • 内部人交易
更多
CELG-RT 简况
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

微牛提供Celgene Corporation(NYSE-CELG RT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CELG RT股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CELG-RT股票基本功能。